DNA gyrase, a bacterial type II topoisomerase, is instrumental in maintaining DNA supercoiling during replication and transcription. Owing to its absence in higher eukaryotes, it represents an ...

These two images demonstrate synthetic lethality with a non-responsive cell line (right) compared to a responder to ATR ...

Andrés Aguilera's laboratory, in collaboration with that of Ralf Wellinger (both professors in the Department of Genetics at the University of Seville in CABIMER) and with PharmaMAR, has identified ...

A new study published in Science Translational Medicine by researchers at The University of Texas MD Anderson Cancer Center ...

Funding to support Phase 1 clinical development of best-in-class PARG inhibitor candidate FORX-428FORX-428 is potential new treatment option for ...

The cancer drugs called PARP inhibitors have a puzzling reputation: even though they are treatment mainstays for multiple forms of cancer, they can damage cancer-killing T cells and disrupt the ...

Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a biotechnology company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, today ...

A new study published today in Science Translational Medicine by researchers at The University of Texas MD Anderson Cancer Center details a therapeutic vulnerability in  patients with an aggressive ...